Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Zika virus kills brain cancer cells - study
The Zika virus, which is spread my mosquitoes, causes serious birth defects.
Findings may be used to treat fatal disease 

A study by US researchers has revealed that Zika virus can kill brain cancer stem cells - the type of cells that are most resistant to standard treatment.

Their findings, published in the Journal of Experimental Medicine, suggest that Zika virus - which causes serious birth defects in humans - could be directed at malignant cells in the brain.

Researchers say their findings have the potential to improve people’s chances against glioblastoma - the most common form of primary brain tumour in adults.

“We showed that Zika virus can kill the kind of glioblastoma cells that tend to be resistant to current treatments and lead to death,” explained co-author Michael Diamond, a professor of Medicine at Washington University School of Medicine.

In the study, researchers from Washington University School of Medicine and the University of California San Diego School of Medicine assessed if the virus could kill stem cells in glioblastomas removed from patients at diagnosis.

Their findings suggest that Zika infection and chemotherapy/radiotherapy compliment each other. While the standard treatment kills the majority of the tumour cells but often leads the stem cells intact, Zika virus attacks the stem cells but bypasses the greater part of the tumour.

“We see Zika one day being used in combination with current therapies to eradicate the whole tumour,” said Chheda, an assistant professor of medicine and neurology.

To see if Zika could be used to treat cancer in a living animal, the researchers injected either Zika virus or salt water (a placebo) into the brain tumours of mice. They found that tumours were markedly smaller in the Zika treated mice two weeks after injection, and those mice survived much longer than the ones injected with salt water.

Researchers say that if Zika virus was to be used in humans, it would have to be injected straight into the brain. If injected anywhere else in the body, the immune system would destroy it before it reaches the brain.

Become a member or log in to add this story to your CPD history

Cold-water dip to raise funds for Vetlife

News Story 1
 The veterinary mental health charity Vetlife is inviting the veterinary community to join it for a sponsored cold-water dip.

The event will take place at Walpole Bay, Margate, on 17 May during Mental Health Awareness Week. Participants of all abilities can join in the challenge and are advised to bring a towel, a hot drink, a snack, and warm clothes to get changed into afterwards.

Those taking part are being asked to try to raise 100 each to support the work of the charity.

Details about how to take part can be found here

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.